MDS Nordion Expands Imaging and Drug Development Capabilities
OTTAWA, June 4 /CNW/ - MDS Nordion, a leading global provider of medical
isotopes and radiopharmaceuticals used in molecular imaging, announced today
that it is collaborating with the University of Ottawa Heart Institute,
Canada's largest cardiovascular health centre, to establish a Molecular
Imaging Centre of Excellence to advance cardiology research.
Molecular imaging is an emerging technology that differs from traditional
medical imaging as it examines changes at the molecular level within the body
to support early disease detection and treatment assessment. MDS Nordion will
invest an estimated US $2.2 million in this new centre, which will be equipped
with a research and development radiochemistry laboratory to support
This collaboration represents a unique opportunity to expand MDS
Nordion's molecular imaging business. Set to open in late 2007 on the
Institute's campus, this new centre will enable the two organizations to
collaborate on joint cardiology research using the latest in molecular imaging
technology. Through this collaboration, MDS Nordion will also provide its
innovative molecular imaging services to large pharmaceutical companies to
help them bring promising new drugs to market faster and with less cost.
For patients, molecular imaging technology can play an important role in
advancing the promise of personalized medicine within the medical community.
In addition to helping medical practitioners detect disease earlier, this
technology can help physicians to better determine the best treatment for each
patient and to monitor their progress throughout treatment.
"We are making a major commitment to innovation with this new centre that
can ultimately make a profound difference in the lives of cardiac patients,"
said Steve West, president of MDS Nordion. "By joining forces with the
University of Ottawa Heart Institute, we have a phenomenal opportunity to
share world-class knowledge, equipment and advanced technology to improve
"This collaboration will enable the Heart Institute to remain at the
forefront of cardiovascular care, education and research," said Dr. Terrence
Ruddy, Chief of Cardiology, University of Ottawa Heart Institute. "The Centre
is an important addition that will add a new dimension to our research
infrastructure. We expect that the research capabilities and opportunities
fuelled by this technology will provide a major step forward in combating and
ultimately eradicating heart disease."
Cardiovascular disease is the number one killer in the United States and
Canada. In the United States, cardiovascular disease is responsible for
36.3 percent of all deaths in 2004, and over 79 million Americans have one or
more forms of the disease. In 2001, heart disease accounted for 33 percent of
all deaths in men and 35 percent of all deaths in women in Canada, according
to the Canadian Health Network.
About MDS Nordion
MDS Nordion (www.mdsnordion.com) is a world leader in medical isotopes,
radiation and related technologies. It is a business unit of MDS Inc.
(TSX:MDS)(NYSE: MDZ). MDS Inc. is a global life sciences company that provides
market-leading products and services for the development of drugs and
diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200
highly skilled people in 28 countries. Find out more at www.mdsinc.com or by
calling 1-888-MDS-7222, 24 hours a day.
About the University of Ottawa Heart Institute
The University of Ottawa Heart Institute is Canada's largest and foremost
cardiovascular health centre dedicated to understanding, treating and
preventing heart disease. The Heart Institute delivers high-tech care with a
personal touch, shapes the way cardiovascular medicine is practiced, and
revolutionizes cardiac treatment and understanding. It builds knowledge
through research and translates discoveries into advanced care. The University
of Ottawa Heart Institute serves the local, national and international
community and is pioneering a new era in heart health. For more information,
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
the CNW Photo Network and archived at http://photos.newswire.ca.
Additional archived images are also available on the CNW Photo Archive
website at http://photos.newswire.ca. Images are free to accredited
members of the media/
For further information:
For further information: Media: Tamra Benjamin, Director, External and
Marketing Communications, MDS Nordion, (613) 697-5815,
email@example.com; Marlene Orton, Senior Manager, Public Affairs,
University of Ottawa Heart Institute, (613) 761-4427, firstname.lastname@example.org;
Investors: Sharon Mathers, Senior Vice-President, Investor Relations and
External Communications, MDS Inc., (416) 675-6777 ext. 34721,